Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
09 March 2022 - 1:00AM
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a clinical-stage life sciences company that is
focused on the development of immunologic‑based therapies for the
prevention and treatment of disease, announced today that its Chief
Executive Officer James Rolke will present a corporate overview
in-person at the 34th Annual Roth Conference, which is being held
at The Ritz Carlton, Laguna Niguel located in Dana Point,
California on March 13-15, 2022.
34th Annual Roth Conference Presentation
Details
Date: |
|
Tuesday, March 15, 2022 |
Time: |
|
8:00 a.m. Pacific Time |
Location: |
|
Blue – Salon 2 @ The Ritz Carlton, Laguna Niguel |
Webcast: |
|
REVB Webcast Link |
A live webcast of the presentation will also be
available in the Investor Relations section of Revelation’s website
at https://www.revbiosciences.com. A replay of the presentation
will be available on Revelation’s website for 30 days following the
event.
Mr. Rolke will be available for one-on-one
meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a clinical-stage
life sciences company focused on the development of
immunologic-based therapies for the prevention and treatment of
disease. Revelation has several product candidates in development.
REVTx-99, the lead therapeutic candidate, is an intranasal
immunomodulator to prevent or treat infections caused by various
respiratory viruses such as SARS-CoV-2, including its variants,
influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is
also being developed for other indications such as: allergic
rhinitis and chronic nasal congestion. REVTx-200 is an intranasal
immunomodulator adjunct to be used in combination with an
intramuscular vaccination for more complete immunity. REVTx-200 is
based on the same technology used in REVTx-99. In addition to
Revelation’s therapeutic pipeline, Revelation is also developing
REVDx-501, a rapid home use diagnostic that can be used to detect
any respiratory viral infection, regardless of virus type or
strain, without the need for specialized instrumentation.
For more information on Revelation, please visit
www.RevBiosciences.com.
Company Contacts
Sandra VedrickVice President, Investor Relations & Human
ResourcesRevelation Biosciences Inc. Email:
svedrick@revbiosciences.com
and
Chester Zygmont, IIIChief Financial OfficerRevelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVBW)
Historical Stock Chart
From May 2024 to Jun 2024
Revelation Biosciences (NASDAQ:REVBW)
Historical Stock Chart
From Jun 2023 to Jun 2024